文献速递头颈外科

da Vinci Xi 经口机器人手术(TORS)的前瞻性可行性、安全性与结局分析

Transoral robotic surgery (TORS) using the da Vinci Xi: prospective analysis of feasibility, safety, and outcomes.
PubMed 文献 · Head Neck · 2021-11-08

前瞻性研究纳入61例头颈癌患者接受Xi-TORS,59例(96.7%)获得充分暴露和肉眼完整切除;术中困难及并发症发生率分别为47.5%和20.3%,术后出血11.9%,无治疗相关死亡。2年总生存率和疾病特异生存率分别为90.5%和95.6%;无患者需长期(>1个月)气管切开,仅2例依赖管饲。作者认为Xi-TORS安全、可行,肿瘤学和功能效果良好。

要点

  • 61例头颈癌患者连续纳入Xi-TORS,59例(96.7%)获得充分暴露和肉眼完整切除。
  • 术中困难发生率47.5%,并发症发生率20.3%,术后出血发生率11.9%,无治疗相关死亡。
  • 2年总生存率90.5%、疾病特异生存率95.6%;无长期(>1个月)气管切开,仅2例依赖管饲。

核心结论

  • 作者认为Xi-TORS安全、可行,具有较高的肿瘤学和功能效果。

研究设计与样本

  • 前瞻性研究,在肿瘤背景下评估da Vinci Xi系统行经口机器人手术(TORS)的可行性、安全性和结局。
  • 连续纳入61例头颈癌患者接受Xi-TORS。

主要发现

  • 59例患者(96.7%)获得充分暴露和肉眼完整切除。
  • 术中困难和并发症分别发生于47.5%和20.3%的患者。
  • 术后出血发生率为11.9%,未发生治疗相关死亡。
  • 2年总生存率为90.5%,2年疾病特异生存率为95.6%。
  • 无患者需长期(>1个月)气管切开,仅2例患者依赖管饲。

关键数值与推荐

  • MD Anderson吞咽障碍量表的功能基线水平在术后12个月恢复。
  • 吞咽生活质量问卷的功能基线水平在术后24个月恢复。
  • QLQ-H&N35评估的生活质量在术后6个月恢复至基线。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The da Vinci Xi system is not Food and Drug Administration approved for transoral robotic surgery (TORS), resulting in limited data. METHODS: This prospective study evaluates the feasibility, safety, and outcomes of Xi-TORS in an oncological setting. RESULTS: Sixty-one patients with head and neck cancer were consecutively included for Xi-TORS. Adequate exposure and macroscopically complete resection were achieved in 59 patients (success rate = 96.7%). Intraoperative difficulties and complications were encountered in 47.5% and 20.3% of patients, respectively. Postoperative hemorrhage occurred in 11.9%; no treatment-related deaths were encountered. Two-year overall survival and disease-specific survival were 90.5% and 95.6%, respectively. No long-term (>1 month) tracheotomies were necessary, and only two patients remained tube-feeding dependent. The functional baseline level was regained at 12 months for the MD Anderson Dysphagia Inventory and at 24 months for the Swallowing quality-of-life questionnaire. QLQ-H&N35-assessed QOL returned to baseline 6 months postoperatively. CONCLUSIONS: Xi-TORS is safe, feasible, and with high oncological and functional effectiveness.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Meulemans J, Vanermen M, Goeleven A, et al. Transoral robotic surgery (TORS) using the da Vinci Xi: prospective analysis of feasibility, safety, and outcomes. Head Neck. 2021. PMID: 34747531. doi:10.1002/hed.26902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。